Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Antiangiogenic therapy of colorectal cancer: state of the art, challenges and new approaches.

Sarmiento R, Longo R, Gasparini G.

Int J Biol Markers. 2012 Dec 27;27(4):e286-94. doi: 10.5301/JBM.2012.10441. Review.

PMID:
23280126
2.

Bevacizumab in HIV-positive patients: concerns about safety and potential for therapeutic use.

Magné N, Chargari C, Levy A, Guy JB, Merrouche Y, Spano JP.

J Chemother. 2014 Aug;26(4):253-5. doi: 10.1179/1973947813Y.0000000109. Epub 2013 Dec 6.

PMID:
24090564
3.

Anti-angiogenic therapies for metastatic colorectal cancer.

Wagner AD, Arnold D, Grothey AA, Haerting J, Unverzagt S.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD005392. doi: 10.1002/14651858.CD005392.pub3. Review.

PMID:
19588372
4.

Current role of bevacizumab in colorectal cancer.

Saltz L.

Clin Adv Hematol Oncol. 2009 Jun;7(6):375-6. No abstract available.

PMID:
19606071
5.

Use of bevacizumab in the treatment of metastatic colorectal cancer.

Raouf S, Bridgewater J, Ellis R, Ferry D, Hill M, Wasan H.

Br J Hosp Med (Lond). 2012 Jan;73(1):25-30. Review. Erratum in: Br J Hosp Med (Lond). 2012 Mar;73(3):174.

PMID:
22241406
6.

The treatment of colorectal carcinoma: standard chemotherapy and beyond.

Eng C, Abbruzzese JL.

Clin Adv Hematol Oncol. 2004 Sep;2(9):592-8. Review.

PMID:
16163242
7.

Bevacizumab targeted therapy: validation of angiogenesis as a key target for advanced colorectal cancer.

Chu E.

Clin Colorectal Cancer. 2004 May;4(1):16. No abstract available.

PMID:
15207014
8.

Validation of the role of angiogenesis as a chemotherapeutic target.

Chu E.

Clin Colorectal Cancer. 2003 Aug;3(2):74-5. No abstract available.

PMID:
12952560
9.

Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.

Gerger A, El-Khoueiry A, Zhang W, Yang D, Singh H, Bohanes P, Ning Y, Winder T, Labonte MJ, Wilson PM, Benhaim L, Paez D, El-Khoueiry R, Absenger G, Lenz HJ.

Clin Cancer Res. 2011 Sep 1;17(17):5783-92. doi: 10.1158/1078-0432.CCR-11-1115. Epub 2011 Jul 26.

10.

[Anti-angiogenic treatment and colorectal cancer].

André T, Tournigand C, Abbas F, Louvet C, de Gramont A; Gercor (French Oncology Research Group).

Bull Cancer. 2007 Jul;94 Spec No:S211-9. Review. French.

PMID:
17846007
11.

[Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].

Jary M, Borg C, Bouché O, Kim S, André T, Bennouna J.

Bull Cancer. 2015 Sep;102(9):758-71. doi: 10.1016/j.bulcan.2015.05.002. Epub 2015 Jul 29. Review. French.

PMID:
26232849
12.

[Metastatic colorectal carcinoma: bevacizumab extends total survival].

[No authors listed]

Pflege Z. 2013 Apr;66(4):252. German. No abstract available.

PMID:
23634556
13.

Future directions with angiogenesis inhibitors in colorectal cancer.

Bilenker JH, Haller DG.

Clin Colorectal Cancer. 2004 Oct;4 Suppl 2:S86-93. Review.

PMID:
15479485
14.

[Novel molecular approaches in the therapy of advanced colorectal carcinoma].

Vanhoefer U.

Onkologie. 2003 Dec;26 Suppl 7:70-4. Review. German.

PMID:
14716146
15.

Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer.

Lee JJ, Chu E.

Clin Colorectal Cancer. 2014 Sep;13(3):135-44. doi: 10.1016/j.clcc.2014.02.001. Epub 2014 Feb 27. Review.

16.

Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients.

Loupakis F, Bocci G, Pasqualetti G, Fornaro L, Salvatore L, Cremolini C, Masi G, Danesi R, Del Tacca M, Falcone A.

Curr Cancer Drug Targets. 2010 Feb;10(1):37-45. Review.

PMID:
20088795
17.

[Angiogenesis targeting in gastro-intestinal cancers].

Meric JB.

Bull Cancer. 2007;94(7 Suppl):F207-15. Review. French.

PMID:
17964998
18.

Maintenance therapy for first-line metastatic colorectal cancer: activity and sustainability.

Strickler JH, Hurwitz HI.

Oncologist. 2012;17(1):9-10. doi: 10.1634/theoncologist.2011-0358. Epub 2012 Jan 10. No abstract available.

20.

Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.

Wagner AD, Thomssen C, Haerting J, Unverzagt S.

Cochrane Database Syst Rev. 2012 Jul 11;(7):CD008941. doi: 10.1002/14651858.CD008941.pub2. Review.

PMID:
22786517

Supplemental Content

Support Center